发明名称 |
Pharmaceutical formulation containing gelling agent |
摘要 |
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. |
申请公布号 |
US9034376(B2) |
申请公布日期 |
2015.05.19 |
申请号 |
US201414460134 |
申请日期 |
2014.08.14 |
申请人 |
Purdue Pharma L.P.;The P.F. Laboratories, Inc.;Purdue Pharmaceuticals L.P. |
发明人 |
Wright Curtis;Oshlack Benjamin;Breder Christopher |
分类号 |
A61K9/20;A61K31/167;A61K9/00;A61K31/439;A61K31/485;A61K47/38;A61K47/36;A61K47/10;A61K45/06;A61K31/192;A61K9/16;A61K47/26 |
主分类号 |
A61K9/20 |
代理机构 |
Lowenstein Sandler LLP |
代理人 |
Lowenstein Sandler LLP |
主权项 |
1. A controlled release oral solid dosage form comprising:
a controlled release matrix comprising a mixture of (i) from 2.5 mg to 320 mg oxycodone or a pharmaceutically acceptable salt thereof; and (ii) a gelling agent comprising polyethylene oxide and hydroxypropylmethylcellulose, the gelling agent in an effective amount to impart a viscosity of at least 10 cP when the dosage form is subjected to tampering by dissolution in from 0.5 to 10 ml of an aqueous liquid; the controlled release matrix providing a therapeutic effect for at least 12 hours when orally administered to a human patient. |
地址 |
Stamford CT US |